Ajay S Kasi, Melinda Riccitelli, Sheila S Kun, Adrianna L Westbrook, George L Silva, Thomas G Keens, Lokesh Guglani
{"title":"COVID-19在先天性中枢性低通气综合征患者中的临床特征","authors":"Ajay S Kasi, Melinda Riccitelli, Sheila S Kun, Adrianna L Westbrook, George L Silva, Thomas G Keens, Lokesh Guglani","doi":"10.1089/ped.2023.0004","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> The clinical course of COVID-19 in patients with congenital central hypoventilation syndrome (CCHS) is unknown. <b><i>Methods:</i></b> We conducted a cross-sectional questionnaire study in 43 patients with CCHS who had COVID-19. <b><i>Results:</i></b> The median age of patients was 11 [interquartile range (IQR) 6-22] years and 53.5% required assisted ventilation (AV) through tracheostomy. Disease severity ranged from asymptomatic infection (12%) to severe illness with hypoxemia (33%) and hypercapnia requiring emergency care/hospitalization (21%), increased AV duration (42%), increased ventilator settings (12%), and supplemental oxygen demand (28%). The median duration to return to baseline AV (<i>n</i> = 20) was 7 (IQR 3-10) days. Patients with polyalanine repeat mutations required increased AV duration compared with those with nonpolyalanine repeat mutations (<i>P</i> = 0.048). Patients with tracheostomy required increased oxygen during illness (<i>P</i> = 0.02). Patients aged ≥18 years took longer to return to baseline AV (<i>P</i> = 0.04). <b><i>Conclusions:</i></b> Our study suggests that all patients with CCHS should be vigilantly monitored during COVID-19 illness.</p>","PeriodicalId":54389,"journal":{"name":"Pediatric Allergy Immunology and Pulmonology","volume":"36 2","pages":"52-56"},"PeriodicalIF":1.1000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Features of COVID-19 in Patients with Congenital Central Hypoventilation Syndrome.\",\"authors\":\"Ajay S Kasi, Melinda Riccitelli, Sheila S Kun, Adrianna L Westbrook, George L Silva, Thomas G Keens, Lokesh Guglani\",\"doi\":\"10.1089/ped.2023.0004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background:</i></b> The clinical course of COVID-19 in patients with congenital central hypoventilation syndrome (CCHS) is unknown. <b><i>Methods:</i></b> We conducted a cross-sectional questionnaire study in 43 patients with CCHS who had COVID-19. <b><i>Results:</i></b> The median age of patients was 11 [interquartile range (IQR) 6-22] years and 53.5% required assisted ventilation (AV) through tracheostomy. Disease severity ranged from asymptomatic infection (12%) to severe illness with hypoxemia (33%) and hypercapnia requiring emergency care/hospitalization (21%), increased AV duration (42%), increased ventilator settings (12%), and supplemental oxygen demand (28%). The median duration to return to baseline AV (<i>n</i> = 20) was 7 (IQR 3-10) days. Patients with polyalanine repeat mutations required increased AV duration compared with those with nonpolyalanine repeat mutations (<i>P</i> = 0.048). Patients with tracheostomy required increased oxygen during illness (<i>P</i> = 0.02). Patients aged ≥18 years took longer to return to baseline AV (<i>P</i> = 0.04). <b><i>Conclusions:</i></b> Our study suggests that all patients with CCHS should be vigilantly monitored during COVID-19 illness.</p>\",\"PeriodicalId\":54389,\"journal\":{\"name\":\"Pediatric Allergy Immunology and Pulmonology\",\"volume\":\"36 2\",\"pages\":\"52-56\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Allergy Immunology and Pulmonology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/ped.2023.0004\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Allergy Immunology and Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ped.2023.0004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
Clinical Features of COVID-19 in Patients with Congenital Central Hypoventilation Syndrome.
Background: The clinical course of COVID-19 in patients with congenital central hypoventilation syndrome (CCHS) is unknown. Methods: We conducted a cross-sectional questionnaire study in 43 patients with CCHS who had COVID-19. Results: The median age of patients was 11 [interquartile range (IQR) 6-22] years and 53.5% required assisted ventilation (AV) through tracheostomy. Disease severity ranged from asymptomatic infection (12%) to severe illness with hypoxemia (33%) and hypercapnia requiring emergency care/hospitalization (21%), increased AV duration (42%), increased ventilator settings (12%), and supplemental oxygen demand (28%). The median duration to return to baseline AV (n = 20) was 7 (IQR 3-10) days. Patients with polyalanine repeat mutations required increased AV duration compared with those with nonpolyalanine repeat mutations (P = 0.048). Patients with tracheostomy required increased oxygen during illness (P = 0.02). Patients aged ≥18 years took longer to return to baseline AV (P = 0.04). Conclusions: Our study suggests that all patients with CCHS should be vigilantly monitored during COVID-19 illness.
期刊介绍:
Pediatric Allergy, Immunology, and Pulmonology is a peer-reviewed journal designed to promote understanding and advance the treatment of respiratory, allergic, and immunologic diseases in children. The Journal delivers original translational, clinical, and epidemiologic research on the most common chronic illnesses of children—asthma and allergies—as well as many less common and rare diseases. It emphasizes the developmental implications of the morphological, physiological, pharmacological, and sociological components of these problems, as well as the impact of disease processes on families.
Pediatric Allergy, Immunology, and Pulmonology coverage includes:
-Functional and genetic immune deficiencies-
Interstitial lung diseases-
Both common and rare respiratory, allergic, and immunologic diseases-
Patient care-
Patient education research-
Public health policy-
International health studies